Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04422366 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04422366 · ClinicalTrials.gov record · last posted 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

StatusRecruiting
PhasePhase 3
Started2020-04-28
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2020-06-04; most recent amendment 2024-06-06. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT04422366
Lead Sponsor Shanghai Bovax Biotechnology Co., Ltd.
Conditions Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1, CIN2, CIN3, VaIN1, VaIN2 +6 more
Enrollment 8,000 participants
Start Date 2020-04-28
Primary Completion 2027-09-15 (estimated)
Study Completion 2029-09-15 (estimated)
Updated on ClinicalTrials.gov 2024-06-07